On January 28, 2020, Achillion Pharmaceuticals was acquired by Alexion Pharmaceuticals, Inc. As part of Alexion, we are continuing to advance a clinical-stage portfolio of orally administered factor D inhibitors and working toward the mission of transforming the lives of people with rare diseases.”